Ted Silver

Ted Silver has been a significant figure at Click Therapeutics since at least 2018. He has been instrumental in securing substantial funding for the company, including $30 million from K2 HealthVentures and $20 million from HSBC. Silver has played a pivotal role in establishing collaborations with major pharmaceutical companies such as Boehringer Ingelheim and Otsuka. His work focuses on the development and commercialization of digital therapeutics for conditions like schizophrenia, major depressive disorder, and migraine. With extensive experience in managing and expanding partnerships, Silver has contributed to the growth of Click Therapeutics’ digital therapeutics initiatives. He has also participated in investor conferences and events to present advancements in the field. Additionally, Silver has been part of the team during the launch of a new brand identity and redesigned website for Click Therapeutics and has been involved in efforts to secure FDA clearance for their digital therapeutics.